Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.

Prior treatment

• Patients with previously pathologically confirmed N1
• Patients with macroscopically involved margin at surgery (R2)
• Prior history of high-intensity focused ultrasound ablation (HIFU), cryosurgery or brachytherapy of the prostate
• Prior pelvic radiotherapy
• Prior hormonal therapy started more than 6 weeks before randomization
• History of inflammatory bowel disease, ataxia telangiectasia, prior rectal or bladder surgery.

Other illness

• Patients with a history of distant metastases
• Other active malignancy, except non-melanoma skin cancer, superficial bladder cancer, or malignancies with a documented disease-free survival for a minimum of 3 years before randomization.

Other

• Patients with a pT4 tumor at prostatectomy
• Patients with a recurrence visible on imaging (local, pelvic, or distant). Pelvic nodes with a small diameter \>1cm and/or positive on PSMA without other explanation, are considered as a pelvic recurrence.
• Latest PSA \> 2ng/ml
• Patients with a IPSS \>20
• Gleason 10 tumor

• Localized adenocarcinoma (cN0M0) of the prostate treated primarily with radical prostatectomy with definitive intent.
• Either persistent PSA after prostatectomy (PSA ≥ 0.1 ng/mL at least 6 weeks after prostatectomy), or biochemical progression (two consecutive rising PSA amounts with a PSA \>0.1 ng/mL , or three consecutive PSA rises)
• WHO PS 0-1
• Age ≥18 years
• Ability to understand and willingness to sign a study-specific informed consent prior to study entry
• Ability to understand and answer the EPIC-26 form in one of the languages available